^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

MA16.06 - Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN

Published date:
08/18/2021
Excerpt:
In CASPIAN, the presence of the HLA-DQB1*03:01 allele was associated with improved OS for durvalumab + tremelimumab + EP treatment.
Secondary therapy:
EP
Trial ID: